Quoin Pharmaceuticals (QNRX) Accumulated Expenses (2020 - 2026)

As of Dec 31, 2025, Quoin Pharmaceuticals' Accumulated Expenses came in at $2.54 million, up 66.0% from the prior year.

• Annual Accumulated Expenses has increased for three consecutive years, with a five-year compound annual growth rate of 21.4% (years ended Dec 2020 to Dec 2025).
• In prior years, Quoin Pharmaceuticals' Accumulated Expenses was $1.53 million in the year ended Dec 31, 2024 (+16.8%), $1.31 million in the year ended Dec 31, 2023 (+11.3%), $1.18 million in the year ended Dec 31, 2022 (-30.2%) and $1.69 million in the year ended Dec 31, 2021 (+75.4%).
• Quarterly Accumulated Expenses has run from a low of $1.18 million in the quarter ended Dec 31, 2022 to a high of $2.59 million in the quarter ended Sep 30, 2023 over five years.
• On a year-over-year basis, Accumulated Expenses increased in six of the last eight quarters, with growth averaging 12.6%.
• The strongest year-over-year quarter for Accumulated Expenses in the past five years was the quarter ended Dec 31, 2021, with growth of 75.4%; the weakest was the quarter ended Sep 30, 2024, with a decline of 42.0%.
• According to Business Quant data, Accumulated Expenses for the three prior quarters was $1.82 million (quarter ended Mar 31, 2026), $2.54 million (quarter ended Dec 31, 2025) and $2.16 million (quarter ended Sep 30, 2025).